{"id":"doi:10.1001/jama.2022.24490","kind":"article","title":"Lecanemab Gains FDA Approval for Early Alzheimer Disease","authors":["Howard D. Larkin"],"author_count":1,"year":2023,"published":"2023-01-18","venue":"JAMA","cited_by":92,"doi":"10.1001/jama.2022.24490","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1001/jama.2022.24490","archive_url":"https://space-kitty.com/papers/doi:10.1001/jama.2022.24490","updated":null,"pmid":"36652625","pmcid":null,"openalex_id":"W4317382447","pdf_url":null,"abstract":null,"abstract_license":null,"license":null,"is_open_access":false,"retracted":false,"peer_reviewed":null,"categories":["Alzheimer's disease research and treatments"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}